Cargando…

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients

CONTEXT: Once-daily HIV treatment regimens are being used in clinical practice with the objective of improving patient acceptance and adherence. OBJECTIVE: To evaluate the efficacy and safety of saquinavir-soft-gelatin capsule (SGC)/ritonavir combination (1600 mg/100 mg) vs efavirenz (600 mg) both o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Julio, Montaner SG, Schutz, Malte, Schwartz, Robert, Jayaweera, Dushyantha T, Burnside, Alfred F, Walmsley, Sharon, Saag, Michael S
Formato:	Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766177/ http://dx.doi.org/10.1186/1758-2652-8-2-36

Ejemplares similares

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro
por: Brilhante, Raimunda Sâmia Nogueira, et al.
Publicado: (2015)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
por: Flamholc, Leo, et al.
Publicado: (2008)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients
por: Boffito, Marta, et al.
Publicado: (2015)

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
por: Knechten, H, et al.
Publicado: (2011)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells
por: Bacigalupo, Ilaria, et al.
Publicado: (2017)

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review
por: Ridjab, Denio A., et al.
Publicado: (2021)

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults
por: Thompson, Melanie, et al.
Publicado: (2018)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro
por: Adamo, Riccardo, et al.
Publicado: (2013)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
por: Lima, Viviane D, et al.
Publicado: (2016)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART
por: Lima, Viviane D, et al.
Publicado: (2006)

947. Stroke demographics and risk factor profile in HIV infected individuals in Florida
por: Ayoade, Folusakin, et al.
Publicado: (2020)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Formulation and evaluation of transparent ibuprofen soft gelatin capsule
por: Lodha, A., et al.
Publicado: (2012)

Challenges of Dissolution Methods Development for Soft Gelatin Capsules
por: Damian, Festo, et al.
Publicado: (2021)

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study
por: López-Cortés, Luis F, et al.
Publicado: (2010)

Comparison between gelatin/carboxymethyl cellulose and gelatin/carboxymethyl nanocellulose in tramadol drug loaded capsule
por: Kadry, Ghada
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cipu2ovn7v6rcbjs1tva3s18at